Professor Belch graduated as a Doctor from the University of Glasgow (MB ChB), becoming a Lecturer within the University Department of Medicine, where she completed her Research MD degree in 1987. She was appointed Senior Lecturer with Honorary Consultant status at the University Department of Medicine in Ninewells Hospital, Dundee, also in 1987, and became Professor of Vascular Medicine in 1995. She was Director of the Tayside Clinical Trials Centre before becoming the Director of the Tayside Medical Science Centre (TASC) and the Tayside R&D Director. She is a founder Fellow of the Academy of Medical Science, and a Fellow of the Royal Society, Edinburgh. She was awarded an OBE in 2016.
She was involved in the first Royal College of Physicians, Edinburgh, PAD Guideline (Medical management of Peripheral Arterial Diseases) in 1998. A second set of guidelines was published in 2007 (Management of peripheral arterial disease), she participated in the recent NICE Quality Standard Advisory Committee (QSAC) for peripheral arterial disease.
Dr Marianne Brodmann is an interventional angiologist, vascular specialist and expert in clinical trials for the treatment of cardiovascular diseases. Dr Brodmann is the Head of Division of Angiology, Head of Clinical Research at Division of Angiology at the Medical University of Graz, Austria.
Active in many national and international societies Dr Brodmann is a Fellow of the European Society of Cardiology, Board Member of the European Union of Medical Specialist (UEMS), past President of the ÖGA (Austrian Society of Angiology) and National Delegate of the IUA (International Union of Angiology).
Research activities include anticoagulation and thrombolysis, new endovascular technologies in the peripheral field and evaluation of the nature of restenosis. She also founded a research establishment for experimental angiology animal models at the University of Graz. Dr Brodmann has participated in over 50 international clinical trials including being the Principal Investigator for the Bioflex I, Lutonix BTK and TOBA-BTK clinical trials and Steering Committee of the CVI Ingenuity trial.
Professor Keith Harding has had a longstanding interest in wound healing and was Director of TIME Institute (Translation, Innovation, Methodology and Engagement) and Head of Wound Healing Research Unit, School of Medicine, Cardiff University and Clinical Lead for Wound Healing in the Cardiff & Vale NHS Trust from 2011 to 2013.
In September 2013 he was appointed as University Dean of Clinical Innovation at Cardiff University and in 2014 was appointed as Medical Director of the Welsh Wound Innovation Centre. He is Editor-in-Chief of the International Wound Journal. He was the First President of the European Pressure Ulcer Advisory Panel, First Recorder of the European Wound Management Association and is a Past President of the European Tissue Repair Society.
He was Chair of a number of Expert Working Groups that produced a range of International Consensus Documents from 2004 to 2016. He has obtained funding of over £50 million from a range of academic, commercial and clinical sources since the Wound Healing Research Unit was created in 1991. He was awarded a CBE in January 2013 for Services to Medicine and Health Care.
William R. Hiatt, MD, is a professor at the University of Colorado School of Medicine, Division of Cardiology with a clinical and research focus in vascular medicine. He is president of CPC Clinical Research which is a university-affiliated, non-profit cardiovascular and clinical trials research organization.
Dr Hiatt is a past chairman of the United States Food and Drug Administration Cardiovascular and Renal Advisory Committee (2003-08) and past member of the FDA Endocrinologic and Metabolism Advisory Committee (2010-2016).
He has been elected several times as Best Doctors in America (most recently in 2012) and in 2014 he was recognized as a Distinguished Scientist of the American Heart Association.
Dr Hiatt serves on the editorial board of the Journal of Vascular Medicine, the Cochrane Review Group, is guest editor for Circulation and section editor for the Journal of the American College of Cardiology.
Research activities include studies evaluating the pathophysiology and epidemiology of peripheral artery disease, mechanisms of supervised exercise as an effective treatment modality for claudication, and numerous clinical trials to develop new therapies for claudication and critical limb ischemia. His research at the CPC has pioneered new methods to control endpoint variability in clinical trials. He has authored 240 peer-reviewed papers.
Paul H.A. Quax, Ph.D. is Professor in Experimental Vascular Medicine at the Department of Vascular Surgery of the Leiden University Medical Centre, the Netherlands. His main research interest is in post-interventional vascular remodelling. Over the past decades he has extensively studied not only the pathophysiology of peripheral artery disease but also of vein graft disease, restenosis and accelerated atherosclerosis.
He has a strong interest in exploring novel therapeutic options to induce neovascularisation, including gene and cell therapy, with the goal to define new strategies for therapeutic angiogenesis and arteriogenesis. He is an Established Investigator of the Netherlands Heart Foundation, Fellow of the American Heart Association and has published more the 175 papers in peer-reviewed journals.
Sam MacHour is formerly the Vice-President and Global Head of Quality, Compliance and Regulatory of Lonza, the world’s largest biologics contract manufacturing company. At Lonza, Sam lead the quality and regulatory strategy development and execution for the company’s nine business units covering biologics, pharmaceuticals, chemicals, food and feed ingredients, cosmetics and high performance products. Prior to joining Lonza, Sam served as the Global Vice President of Quality and Regulatory Compliance at Becton Dickinson, one of the world’s largest MedTech. Prior to Becton, Sam served at different positions of increased responsibility, technical and executive, helping the world’s largest and medium size pharma, biologics, medical device, and cosmetic companies in North America, Europe & Asia, transform, compete and gain leadership in the areas of product development, operations, drug/device quality/commercialization and business development. More recently, Sam lead the early stage identification and worked to secure safe grounds for a $5.5B acquisition that completed in 2017 and transformed the company’s global product portfolio and business value proposition significantly for the future.
Sam id the Founder of Executives Without Borders (http://www.executiveswithoutborders.org/), the world’s largest volunteer based not for profit organisation. Executives Without Borders serves as the bridge between those in the non-profit world and those in the business world, making it easier for them to work together and enhance lives of thousands of communities around the world. Sam holds an MSC in Nuclear Physics from Concordia University and is a Graduate of Harvard’s General Management Program.